<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468650</url>
  </required_header>
  <id_info>
    <org_study_id>A1481251</org_study_id>
    <nct_id>NCT00468650</nct_id>
  </id_info>
  <brief_title>A Multicenter, Open Label, To Evaluate The Efficacy And Satisfaction Of Patrex® In Men With Erectile Dysfunction.</brief_title>
  <official_title>A Multicenter, Open Label, High Dose (100mg) Rapid Titration Study, To Evaluate The Efficacy And Satisfaction Of Patrex® (Sildenafil Citrate) In Men With Erectile Dysfunction In Mexico.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter open label study to assess the efficacy of sildenafil rapid dose titration to
      100 mg in men with erectile dysfunction, based on the Erectile Function (EF) domain score of
      the International Index of Erectile Function (IIEF) questionnaire.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Baseline to Week 6 Last Observation Carried Forward (LOCF)</measure>
    <time_frame>Week 6 LOCF</time_frame>
    <description>IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 &amp; 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 &amp; 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 &amp; 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Baseline</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Baseline</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Baseline</measure>
    <time_frame>Week 2, Week 4, and Week 6</time_frame>
    <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Baseline</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Erection Questionnaire (QEQ): Total Score - Change From Baseline</measure>
    <time_frame>Week 2, Week 4, and Week 6</time_frame>
    <description>QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Erection Questionnaire (QEQ): Total Score- Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Experience Questionnaire (Sex-Q): Erection Domain - Change From Baseline</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Baseline</measure>
    <time_frame>Week 2, Week 4, and Week 6</time_frame>
    <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Baseline</measure>
    <time_frame>Week 2, Week 4, and Week 6</time_frame>
    <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From Baseline</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at baseline. Percent of &quot;Yes&quot; responses to Question 1 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 1 [Were you able to achieve at least some erection (some enlargement of the penis)?] = Yes) / (number of occasions where Question 1 was answered Yes or No)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at Week 2. Percent of &quot;Yes&quot; responses to Question 1 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 1 [Were you able to achieve at least some erection (some enlargement of the penis)?] = Yes) / (number of occasions where Question 1 was answered Yes or No)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Baseline</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at baseline. Percent of &quot;Yes&quot; responses to SEP Question 2 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 2 [&quot;Were you able to insert your penis into your partner's vagina?&quot;] = &quot;Yes&quot;) / (number of occasions where SEP Question 2 was answered &quot;Yes&quot; or &quot;No&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at Week 2. Percent of &quot;Yes&quot; responses to SEP Question 2 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 2 [&quot;Were you able to insert your penis into your partner's vagina?&quot;] = &quot;Yes&quot;) / (number of occasions where SEP Question 2 was answered &quot;Yes&quot; or &quot;No&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From Baseline</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at baseline. Percent of &quot;Yes&quot; responses to SEP Question 2 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 3 [Did your erection last long enough for you to have successful intercourse?] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at Week 2. Percent of &quot;Yes&quot; responses to SEP Question 2 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 3 [Did your erection last long enough for you to have successful intercourse?] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Baseline</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at baseline. Percent of &quot;Yes&quot; responses to SEP Question 4 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 4 [&quot;Were you satisfied with the hardness of your erection?&quot;] = &quot;Yes&quot;) / (number of occasions where SEP Question 4 was answered &quot;Yes&quot; or &quot;No&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at Week 2. Percent of &quot;Yes&quot; responses to SEP Question 4 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 4 [&quot;Were you satisfied with the hardness of your erection?&quot;] = &quot;Yes&quot;) / (number of occasions where SEP Question 4 was answered &quot;Yes&quot; or &quot;No&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Baseline</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at baseline. Percent of &quot;Yes&quot; responses to SEP Question 5 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 5 [&quot;Were you satisfied with this sexual encounter?&quot;] = &quot;Yes&quot;) / (number of occasions where SEP Question 5 was answered &quot;Yes&quot; or &quot;No&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at Week 2. Percent of &quot;Yes&quot; responses to SEP Question 5 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 5 [&quot;Were you satisfied with this sexual encounter?&quot;] = &quot;Yes&quot;) / (number of occasions where SEP Question 5 was answered &quot;Yes&quot; or &quot;No&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Baseline</measure>
    <time_frame>Week 2, Week 4, and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at baseline. Percent of &quot;Yes&quot; responses to SEP Q3 based on attempts with sexual stimulation (SS): 100* (number of attempts with SS where SEP Q3 [Did your erection last long enough for you to have successful intercourse?] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at Week 2. Percent of &quot;Yes&quot; responses to SEP Q3 based on attempts with sexual stimulation (SS): 100* (number of attempts with SS where SEP Q3 [Did your erection last long enough for you to have successful intercourse?] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Baseline</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (3= hard enough for penetration [but not completely hard]) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (3= hard enough for penetration [but not completely hard]) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline</measure>
    <time_frame>Week 2, Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (hard enough for penetration [but not completely hard]) or 4 (completely hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (hard enough for penetration [but not completely hard]) or 4 (completely hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive Patrex® 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to Patrex® 100 mg PRN for the following four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil citrate</intervention_name>
    <description>Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.</description>
    <arm_group_label>Open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented Clinical diagnosis of Erectile Dysfunction (ED) by International Index of
             Erectile Function (IIEF) Erectile Function (EF) Domain score less than or equal to 25.

          -  Subjects must be in a stable relationship

        Exclusion Criteria:

          -  Subject with resting sitting hypotension (BP &lt;90/50 mmHg) or hypertension (BP&gt;170/110
             mmHg) and orthostatic hypotension.

          -  Subjects receiving any PDE (Phosphodiesterase)-5 inhibitors within 4 weeks prior to
             the date of screening.

          -  Subjects with severe hepatic impairment, a known history of retinitis pigmentare.

          -  Subjects with significant cardiovascular disease in the last 3 months (per medical
             history.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>D.f.</state>
        <zip>11520</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>D.f.</state>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Naucalpan</city>
        <state>Edo. de México</state>
        <zip>53100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45040</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Durango</city>
        <zip>34300</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Naucalpan Edo. de Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481251&amp;StudyName=A%20Multicenter%2C%20Open%20Label%2C%20%20To%20Evaluate%20The%20Efficacy%20And%20Satisfaction%20Of%20Patrex%AE%20In%20Men%20With%20Erectile%20Dysfunction.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2007</study_first_submitted>
  <study_first_submitted_qc>May 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2007</study_first_posted>
  <results_first_submitted>February 12, 2009</results_first_submitted>
  <results_first_submitted_qc>February 12, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 16, 2009</results_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Eligible subjects had to have at least 2 attempts at sexual intercourse during the 2 week screening phase to begin the sildenafil citrate 50mg treatment at baseline.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Open Label Sildenafil Citrate</title>
          <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label Sildenafil Citrate</title>
          <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Baseline to Week 6 Last Observation Carried Forward (LOCF)</title>
        <description>IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 &amp; 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.</description>
        <time_frame>Week 6 LOCF</time_frame>
        <population>Modified intent to treat (MITT) population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, last assessment collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Baseline to Week 6 Last Observation Carried Forward (LOCF)</title>
          <description>IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 &amp; 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.</description>
          <population>Modified intent to treat (MITT) population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, last assessment collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.96" spread="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary hypothesis to be tested is whether there is a significant improvement in the IIEF EF domain at the end of the 100 mg period, as compared to the baseline (Week 0) score. Sample size (N=115) provides more than 90% power to detect a change from baseline of 10 in the primary efficacy variable, assuming a standard deviation of 9, using the two-sided, single-sample t-test with significance level (alpha) of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Statistical significance will be declared if the p-value is &lt;0.05.
Change from Baseline: Week 6 (LOCF) minus Baseline</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.96</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>10.00</ci_lower_limit>
            <ci_upper_limit>11.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6</title>
        <description>IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 &amp; 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6</title>
          <description>IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 &amp; 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.14" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.57" spread="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.93" spread="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.95" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>7.14</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.17</ci_lower_limit>
            <ci_upper_limit>8.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.57</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>9.56</ci_lower_limit>
            <ci_upper_limit>11.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.93</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>9.93</ci_lower_limit>
            <ci_upper_limit>11.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 endpoint minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.95</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>9.97</ci_lower_limit>
            <ci_upper_limit>11.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2</title>
        <description>IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 &amp; 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and, thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2</title>
          <description>IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 &amp; 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.48</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.74</ci_lower_limit>
            <ci_upper_limit>4.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2 For the secondary outcome, the change in IIEF-EF domain from the end of 50 mg period (Week 2) to the end of 100 mg period (Week 6), the sample size (N=115) provides more than 80% power to detect a mean change of 1.75 points, assuming a standard deviation of 6, using the two-sided, single sample t-test with significance level (alpha) of 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.88</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.05</ci_lower_limit>
            <ci_upper_limit>4.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2 For the secondary outcome, the change in IIEF-EF domain from the end of 50 mg period (Week 2) to the end of 100 mg period (Week 6), the sample size (N=115) provides more than 80% power to detect a mean change of 1.75 points, assuming a standard deviation of 6, using the two-sided, single sample t-test with significance level (alpha) of 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.86</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.04</ci_lower_limit>
            <ci_upper_limit>4.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2 For the secondary outcome, the change in IIEF-EF domain from the end of 50 mg period (Week 2) to the end of 100 mg period (Week 6), the sample size (N=115) provides more than 80% power to detect a mean change of 1.75 points, assuming a standard deviation of 6, using the two-sided, single sample t-test with significance level (alpha) of 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.86</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.04</ci_lower_limit>
            <ci_upper_limit>4.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Baseline</title>
        <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and, thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Baseline</title>
          <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.89</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.45</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.46</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.02</ci_lower_limit>
            <ci_upper_limit>2.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.59</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.13</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.63</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.17</ci_lower_limit>
            <ci_upper_limit>3.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.59</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.14</ci_lower_limit>
            <ci_upper_limit>3.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2</title>
        <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2</title>
          <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.61</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.75</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.74</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.74</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Baseline</title>
        <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and, thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Baseline</title>
          <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.43</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.00</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.65</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.25</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.89</ci_lower_limit>
            <ci_upper_limit>2.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.26</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.90</ci_lower_limit>
            <ci_upper_limit>2.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.28</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.91</ci_lower_limit>
            <ci_upper_limit>2.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2</title>
        <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2</title>
          <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.55</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.81</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.83</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.83</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Baseline</title>
        <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.</description>
        <time_frame>Week 2, Week 4, and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and, thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Baseline</title>
          <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.18" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.70" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.18</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.73</ci_lower_limit>
            <ci_upper_limit>3.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.38</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.94</ci_lower_limit>
            <ci_upper_limit>4.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.73</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.25</ci_lower_limit>
            <ci_upper_limit>5.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.70</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.23</ci_lower_limit>
            <ci_upper_limit>5.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.72</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.25</ci_lower_limit>
            <ci_upper_limit>5.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2</title>
        <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2</title>
          <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.20</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.54</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.54</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.54</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Baseline</title>
        <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and, thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Baseline</title>
          <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.73</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.28</ci_lower_limit>
            <ci_upper_limit>3.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.67</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.20</ci_lower_limit>
            <ci_upper_limit>4.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.92</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.44</ci_lower_limit>
            <ci_upper_limit>4.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.91</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.44</ci_lower_limit>
            <ci_upper_limit>4.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.89</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.42</ci_lower_limit>
            <ci_upper_limit>4.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2</title>
        <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2</title>
          <description>IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.97</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.21</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.92</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.20</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.20</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Erection Questionnaire (QEQ): Total Score - Change From Baseline</title>
        <description>QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.</description>
        <time_frame>Week 2, Week 4, and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and, thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Erection Questionnaire (QEQ): Total Score - Change From Baseline</title>
          <description>QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.71" spread="25.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.21" spread="26.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.53" spread="26.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.28" spread="27.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.05" spread="27.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>32.71</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>25.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>27.98</ci_lower_limit>
            <ci_upper_limit>37.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>46.21</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>26.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>41.29</ci_lower_limit>
            <ci_upper_limit>51.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>45.53</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>26.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>40.44</ci_lower_limit>
            <ci_upper_limit>50.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>45.28</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>27.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>40.25</ci_lower_limit>
            <ci_upper_limit>50.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>45.05</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>27.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>39.99</ci_lower_limit>
            <ci_upper_limit>50.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Erection Questionnaire (QEQ): Total Score- Change From Week 2</title>
        <description>QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Erection Questionnaire (QEQ): Total Score- Change From Week 2</title>
          <description>QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.</description>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.84" spread="21.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.07" spread="24.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.69" spread="24.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.69" spread="24.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>13.84</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>21.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>9.89</ci_lower_limit>
            <ci_upper_limit>17.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>13.07</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.49</ci_lower_limit>
            <ci_upper_limit>17.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>12.69</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.14</ci_lower_limit>
            <ci_upper_limit>17.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>12.69</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.14</ci_lower_limit>
            <ci_upper_limit>17.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sexual Experience Questionnaire (Sex-Q): Erection Domain - Change From Baseline</title>
        <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and, thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sexual Experience Questionnaire (Sex-Q): Erection Domain - Change From Baseline</title>
          <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41" spread="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.85" spread="4.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.21" spread="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.28" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.25" spread="5.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.41</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.59</ci_lower_limit>
            <ci_upper_limit>6.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>8.85</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.92</ci_lower_limit>
            <ci_upper_limit>9.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>9.21</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.23</ci_lower_limit>
            <ci_upper_limit>10.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>9.28</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.32</ci_lower_limit>
            <ci_upper_limit>10.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>9.25</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.28</ci_lower_limit>
            <ci_upper_limit>10.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2</title>
        <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2</title>
          <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" spread="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" spread="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" spread="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.51</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.78</ci_lower_limit>
            <ci_upper_limit>4.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.91</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.08</ci_lower_limit>
            <ci_upper_limit>4.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.91</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.09</ci_lower_limit>
            <ci_upper_limit>4.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.91</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.09</ci_lower_limit>
            <ci_upper_limit>4.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Baseline</title>
        <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome</description>
        <time_frame>Week 2, Week 4, and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and, thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Baseline</title>
          <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.68" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.94" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.59" spread="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.63" spread="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.64" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.68</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.77</ci_lower_limit>
            <ci_upper_limit>7.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>9.94</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.96</ci_lower_limit>
            <ci_upper_limit>10.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.59</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>9.62</ci_lower_limit>
            <ci_upper_limit>11.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.63</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>9.68</ci_lower_limit>
            <ci_upper_limit>11.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.64</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>9.68</ci_lower_limit>
            <ci_upper_limit>11.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2</title>
        <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2</title>
          <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" spread="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.03" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.01" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.01" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.29</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.52</ci_lower_limit>
            <ci_upper_limit>4.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.03</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.06</ci_lower_limit>
            <ci_upper_limit>5.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.01</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.06</ci_lower_limit>
            <ci_upper_limit>4.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.01</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.06</ci_lower_limit>
            <ci_upper_limit>4.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Baseline</title>
        <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.</description>
        <time_frame>Week 2, Week 4, and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and, thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Baseline</title>
          <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.23" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.79</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.33</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.23</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.74</ci_lower_limit>
            <ci_upper_limit>4.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.74</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.20</ci_lower_limit>
            <ci_upper_limit>5.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.78</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.25</ci_lower_limit>
            <ci_upper_limit>5.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.76</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.23</ci_lower_limit>
            <ci_upper_limit>5.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2</title>
        <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2</title>
          <description>Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.49</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.96</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.57</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.98</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.59</ci_lower_limit>
            <ci_upper_limit>2.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.98</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.59</ci_lower_limit>
            <ci_upper_limit>2.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From Baseline</title>
        <description>Mean change: mean change at each visit minus mean at baseline. Percent of “Yes” responses to Question 1 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 1 [Were you able to achieve at least some erection (some enlargement of the penis)?] = Yes) / (number of occasions where Question 1 was answered Yes or No)</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and, thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From Baseline</title>
          <description>Mean change: mean change at each visit minus mean at baseline. Percent of “Yes” responses to Question 1 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 1 [Were you able to achieve at least some erection (some enlargement of the penis)?] = Yes) / (number of occasions where Question 1 was answered Yes or No)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Question 1 (Week 2) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.84" spread="28.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 1 (Week 4) N=108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.18" spread="27.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 1 (Week 6) N=105</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.29" spread="28.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 1 (Week 6 LOCF) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.96" spread="28.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 1 (Week 6 Endpoint) N=108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.95" spread="28.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>8.84</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>28.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.42</ci_lower_limit>
            <ci_upper_limit>14.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.18</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>27.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.93</ci_lower_limit>
            <ci_upper_limit>15.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>12.29</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>28.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.70</ci_lower_limit>
            <ci_upper_limit>17.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>11.96</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>28.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.61</ci_lower_limit>
            <ci_upper_limit>17.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>11.95</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>28.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.51</ci_lower_limit>
            <ci_upper_limit>17.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2</title>
        <description>Mean change: mean change at each visit minus mean at Week 2. Percent of “Yes” responses to Question 1 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 1 [Were you able to achieve at least some erection (some enlargement of the penis)?] = Yes) / (number of occasions where Question 1 was answered Yes or No)</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2</title>
          <description>Mean change: mean change at each visit minus mean at Week 2. Percent of “Yes” responses to Question 1 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 1 [Were you able to achieve at least some erection (some enlargement of the penis)?] = Yes) / (number of occasions where Question 1 was answered Yes or No)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Question 1 (Week 4) N=111</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="14.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 1 (Week 6) N=108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="14.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 1 (Week 6 LOCF) N=113</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 1 (Week 6 Endpoint) N=111</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" spread="14.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3324</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.37</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.42</ci_lower_limit>
            <ci_upper_limit>4.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0249</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.12</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>5.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0249</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.98</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>5.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0249</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.04</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>5.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Baseline</title>
        <description>Mean change: mean change at each visit minus mean at baseline. Percent of “Yes” responses to SEP Question 2 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 2 [“Were you able to insert your penis into your partner’s vagina?”] = “Yes”) / (number of occasions where SEP Question 2 was answered “Yes” or “No”).</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Baseline</title>
          <description>Mean change: mean change at each visit minus mean at baseline. Percent of “Yes” responses to SEP Question 2 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 2 [“Were you able to insert your penis into your partner’s vagina?”] = “Yes”) / (number of occasions where SEP Question 2 was answered “Yes” or “No”).</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Question 2 (Week 2) N=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.37" spread="30.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 2 (Week 4) N=100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.15" spread="32.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 2 (Week 6) N=97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.22" spread="32.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 2 (Week 6 LOCF) N=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.33" spread="31.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 2 (Week 6 Endpoint) N=100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.68" spread="32.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>15.37</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>30.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>9.38</ci_lower_limit>
            <ci_upper_limit>21.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>17.15</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>32.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>10.76</ci_lower_limit>
            <ci_upper_limit>23.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>18.22</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>32.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>11.68</ci_lower_limit>
            <ci_upper_limit>24.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>17.33</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>31.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>11.07</ci_lower_limit>
            <ci_upper_limit>23.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>17.68</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>32.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>11.31</ci_lower_limit>
            <ci_upper_limit>24.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2</title>
        <description>Mean change: mean change at each visit minus mean at Week 2. Percent of “Yes” responses to SEP Question 2 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 2 [“Were you able to insert your penis into your partner’s vagina?”] = “Yes”) / (number of occasions where SEP Question 2 was answered “Yes” or “No”).</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2</title>
          <description>Mean change: mean change at each visit minus mean at Week 2. Percent of “Yes” responses to SEP Question 2 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 2 [“Were you able to insert your penis into your partner’s vagina?”] = “Yes”) / (number of occasions where SEP Question 2 was answered “Yes” or “No”).</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Question 2 (Week 4) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 2 (Week 6) N=107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="12.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 2 (Week 6 LOCF) N=112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 2 (Week 6 Endpoint) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="12.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1061</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.46</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>9.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3237</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.18</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.18</ci_lower_limit>
            <ci_upper_limit>3.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3236</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.13</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.13</ci_lower_limit>
            <ci_upper_limit>3.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3236</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.15</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.15</ci_lower_limit>
            <ci_upper_limit>3.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From Baseline</title>
        <description>Mean change: mean change at each visit minus mean at baseline. Percent of “Yes” responses to SEP Question 2 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 3 [Did your erection last long enough for you to have successful intercourse?] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From Baseline</title>
          <description>Mean change: mean change at each visit minus mean at baseline. Percent of “Yes” responses to SEP Question 2 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 3 [Did your erection last long enough for you to have successful intercourse?] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Question 3 (Week 2) N=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.96" spread="38.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 3 (Week 4) N=100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.78" spread="35.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 3 (Week 6) N=97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.23" spread="35.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 3 (Week 6 LOCF) N=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.15" spread="35.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 3 (Week 6 Endpoint) N=100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.60" spread="35.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>56.96</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>38.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>49.31</ci_lower_limit>
            <ci_upper_limit>64.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>70.78</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>35.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>63.74</ci_lower_limit>
            <ci_upper_limit>77.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>71.23</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>35.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>64.02</ci_lower_limit>
            <ci_upper_limit>78.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>72.15</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>35.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>65.20</ci_lower_limit>
            <ci_upper_limit>79.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>71.60</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>35.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>64.54</ci_lower_limit>
            <ci_upper_limit>78.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2</title>
        <description>Mean change: mean change at each visit minus mean at Week 2. Percent of “Yes” responses to SEP Question 2 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 3 [Did your erection last long enough for you to have successful intercourse?] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2</title>
          <description>Mean change: mean change at each visit minus mean at Week 2. Percent of “Yes” responses to SEP Question 2 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 3 [Did your erection last long enough for you to have successful intercourse?] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Question 3 (Week 4) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.56" spread="30.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 3 (Week 6) N=107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.25" spread="31.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 3 (Week 6 LOCF) N=112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.51" spread="31.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 3 (Week 6 Endpoint) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.77" spread="32.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>13.56</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>30.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.72</ci_lower_limit>
            <ci_upper_limit>19.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>14.25</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>31.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.25</ci_lower_limit>
            <ci_upper_limit>20.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>14.51</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>31.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.56</ci_lower_limit>
            <ci_upper_limit>20.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>14.77</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>32.00</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.72</ci_lower_limit>
            <ci_upper_limit>20.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Baseline</title>
        <description>Mean change: mean change at each visit minus mean at baseline. Percent of “Yes” responses to SEP Question 4 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 4 [“Were you satisfied with the hardness of your erection?”] = “Yes”) / (number of occasions where SEP Question 4 was answered “Yes” or “No”).</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Baseline</title>
          <description>Mean change: mean change at each visit minus mean at baseline. Percent of “Yes” responses to SEP Question 4 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 4 [“Were you satisfied with the hardness of your erection?”] = “Yes”) / (number of occasions where SEP Question 4 was answered “Yes” or “No”).</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Question 4 (Week 2) N=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.58" spread="41.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 4 (Week 4) N=100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.29" spread="37.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 4(Week 6) N=97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.69" spread="37.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 4 (Week 6 LOCF) N=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.79" spread="36.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 4 (Week 6 Endpoint) N=100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.36" spread="36.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>58.58</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>41.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>50.48</ci_lower_limit>
            <ci_upper_limit>66.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>76.29</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>37.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>68.90</ci_lower_limit>
            <ci_upper_limit>83.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>77.69</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>37.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>70.18</ci_lower_limit>
            <ci_upper_limit>85.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>78.79</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>36.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>71.59</ci_lower_limit>
            <ci_upper_limit>85.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>78.36</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>36.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>71.04</ci_lower_limit>
            <ci_upper_limit>85.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2</title>
        <description>Mean change: mean change at each visit minus mean at Week 2. Percent of “Yes” responses to SEP Question 4 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 4 [“Were you satisfied with the hardness of your erection?”] = “Yes”) / (number of occasions where SEP Question 4 was answered “Yes” or “No”).</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2</title>
          <description>Mean change: mean change at each visit minus mean at Week 2. Percent of “Yes” responses to SEP Question 4 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 4 [“Were you satisfied with the hardness of your erection?”] = “Yes”) / (number of occasions where SEP Question 4 was answered “Yes” or “No”).</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Question 4 (Week 4) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.90" spread="36.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 4 (Week 6) N=107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.50" spread="36.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 4 (Week 6 LOCF) N=112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.52" spread="36.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 4 (Week 6 Endpoint) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.88" spread="37.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>17.90</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>36.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>10.98</ci_lower_limit>
            <ci_upper_limit>24.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>19.50</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>36.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>12.44</ci_lower_limit>
            <ci_upper_limit>26.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>19.52</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>36.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>12.59</ci_lower_limit>
            <ci_upper_limit>26.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>19.88</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>37.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>12.84</ci_lower_limit>
            <ci_upper_limit>26.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Baseline</title>
        <description>Mean change: mean change at each visit minus mean at baseline. Percent of “Yes” responses to SEP Question 5 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 5 [“Were you satisfied with this sexual encounter?”] = “Yes”) / (number of occasions where SEP Question 5 was answered “Yes” or “No”)</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Baseline</title>
          <description>Mean change: mean change at each visit minus mean at baseline. Percent of “Yes” responses to SEP Question 5 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 5 [“Were you satisfied with this sexual encounter?”] = “Yes”) / (number of occasions where SEP Question 5 was answered “Yes” or “No”)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Question 5 (Week 2) N=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.34" spread="42.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 5 (Week 4) N=100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.72" spread="40.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 5 (Week 6) N=97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.63" spread="40.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 5 (Week 6 LOCF) N=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.07" spread="40.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 5 (Week 6 Endpoint) N=100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.51" spread="40.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>57.34</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>42.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>48.93</ci_lower_limit>
            <ci_upper_limit>65.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>70.72</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>40.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>62.72</ci_lower_limit>
            <ci_upper_limit>78.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>70.63</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>40.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>62.41</ci_lower_limit>
            <ci_upper_limit>78.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>72.07</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>40.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>64.16</ci_lower_limit>
            <ci_upper_limit>79.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>71.51</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>40.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>63.48</ci_lower_limit>
            <ci_upper_limit>79.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2</title>
        <description>Mean change: mean change at each visit minus mean at Week 2. Percent of “Yes” responses to SEP Question 5 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 5 [“Were you satisfied with this sexual encounter?”] = “Yes”) / (number of occasions where SEP Question 5 was answered “Yes” or “No”)</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2</title>
          <description>Mean change: mean change at each visit minus mean at Week 2. Percent of “Yes” responses to SEP Question 5 based on occasions (= sexual stimulation): 100*(number of occasions where SEP Question 5 [“Were you satisfied with this sexual encounter?”] = “Yes”) / (number of occasions where SEP Question 5 was answered “Yes” or “No”)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Question 5 (Week 4) N=109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.10" spread="29.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 5 (Week 6) N=106</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.11" spread="32.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 5 (Week 6 LOCF) N=111</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.47" spread="31.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 5 (Week 6 Endpoint) N=109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.72" spread="32.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>13.10</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.58</ci_lower_limit>
            <ci_upper_limit>18.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>14.11</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>32.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.84</ci_lower_limit>
            <ci_upper_limit>20.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>13.47</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>31.92</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.47</ci_lower_limit>
            <ci_upper_limit>19.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>13.72</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>32.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.61</ci_lower_limit>
            <ci_upper_limit>19.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Baseline</title>
        <description>Mean change: mean change at each visit minus mean at baseline. Percent of “Yes” responses to SEP Q3 based on attempts with sexual stimulation (SS): 100* (number of attempts with SS where SEP Q3 [Did your erection last long enough for you to have successful intercourse?] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)</description>
        <time_frame>Week 2, Week 4, and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and, thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Baseline</title>
          <description>Mean change: mean change at each visit minus mean at baseline. Percent of “Yes” responses to SEP Q3 based on attempts with sexual stimulation (SS): 100* (number of attempts with SS where SEP Q3 [Did your erection last long enough for you to have successful intercourse?] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.96" spread="38.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.78" spread="35.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.23" spread="35.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.15" spread="35.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.60" spread="35.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>56.96</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>38.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>49.31</ci_lower_limit>
            <ci_upper_limit>64.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>70.78</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>35.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>63.74</ci_lower_limit>
            <ci_upper_limit>77.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>71.23</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>35.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>64.02</ci_lower_limit>
            <ci_upper_limit>78.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>72.15</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>35.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>65.20</ci_lower_limit>
            <ci_upper_limit>79.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>71.60</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>35.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>64.54</ci_lower_limit>
            <ci_upper_limit>78.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2</title>
        <description>Mean change: mean change at each visit minus mean at Week 2. Percent of “Yes” responses to SEP Q3 based on attempts with sexual stimulation (SS): 100* (number of attempts with SS where SEP Q3 [Did your erection last long enough for you to have successful intercourse?] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2</title>
          <description>Mean change: mean change at each visit minus mean at Week 2. Percent of “Yes” responses to SEP Q3 based on attempts with sexual stimulation (SS): 100* (number of attempts with SS where SEP Q3 [Did your erection last long enough for you to have successful intercourse?] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.56" spread="30.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.25" spread="31.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 LOCF (N=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.51" spread="31.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 Endpoint (N=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.77" spread="32.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>13.56</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>30.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.72</ci_lower_limit>
            <ci_upper_limit>19.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>14.25</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>31.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.25</ci_lower_limit>
            <ci_upper_limit>20.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>14.51</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>31.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.56</ci_lower_limit>
            <ci_upper_limit>20.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>14.77</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>32.00</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.72</ci_lower_limit>
            <ci_upper_limit>20.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Baseline</title>
        <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and, thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Baseline</title>
          <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1 (Week 2) N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.58" spread="37.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 (Week 4) N=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.55" spread="35.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 (Week 6) N=98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.53" spread="36.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 (Week 6 LOCF) N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.44" spread="36.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 (Week 6 Endpoint) N=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.86" spread="36.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-12.58</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>37.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-19.96</ci_lower_limit>
            <ci_upper_limit>-5.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-20.55</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>35.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-27.47</ci_lower_limit>
            <ci_upper_limit>-13.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-22.53</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>36.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-29.88</ci_lower_limit>
            <ci_upper_limit>-15.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-21.44</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>36.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-28.49</ci_lower_limit>
            <ci_upper_limit>-14.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-21.86</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>36.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-29.03</ci_lower_limit>
            <ci_upper_limit>-14.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2</title>
        <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2</title>
          <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1 (Week 4) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.79" spread="22.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 (Week 6) N=107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.85" spread="23.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 (Week 6 LOCF) N=112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.43" spread="24.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 (Week 6 Endpoint) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.57" spread="24.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-6.79</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.06</ci_lower_limit>
            <ci_upper_limit>-2.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-6.85</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>23.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.26</ci_lower_limit>
            <ci_upper_limit>-2.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-7.43</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.97</ci_lower_limit>
            <ci_upper_limit>-2.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-7.57</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.18</ci_lower_limit>
            <ci_upper_limit>-2.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline</title>
        <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline</title>
          <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>Per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 2 (Week 2) N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.87" spread="34.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 (Week 4) N=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.74" spread="32.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 (Week 6) N=98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.78" spread="33.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 (Week 6 LOCF) N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.13" spread="33.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 (Week 6 Endpoint) N=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.40" spread="33.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0045</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-9.87</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>34.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-16.60</ci_lower_limit>
            <ci_upper_limit>-3.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-11.74</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>32.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-18.22</ci_lower_limit>
            <ci_upper_limit>-5.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-12.78</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>33.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-19.51</ci_lower_limit>
            <ci_upper_limit>-6.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-13.13</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>33.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-19.76</ci_lower_limit>
            <ci_upper_limit>-6.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-12.40</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>33.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-18.94</ci_lower_limit>
            <ci_upper_limit>-5.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2</title>
        <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2</title>
          <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 2 (Week 4) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.39" spread="22.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 (Week 6) N=107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" spread="20.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 (Week 6 LOCF) N=112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.71" spread="22.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 (Week 6 Endpoint) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.76" spread="22.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2567</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.39</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.00</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.55</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3435</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.91</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>20.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.88</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2000</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.71</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.89</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2000</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.76</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.01</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline</title>
        <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (3= hard enough for penetration [but not completely hard]) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline</title>
          <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (3= hard enough for penetration [but not completely hard]) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 (Week 2) N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.82" spread="56.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 (Week 4) N=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.16" spread="59.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 (Week 6) N=98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.79" spread="60.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 (Week 6 LOCF) N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.27" spread="61.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 (Week 6 Endpoint) N=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.87" spread="60.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0558</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-10.82</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>56.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-21.91</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-29.16</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>59.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-40.96</ci_lower_limit>
            <ci_upper_limit>-17.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-30.79</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>60.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-43.00</ci_lower_limit>
            <ci_upper_limit>-18.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-30.27</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>61.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-42.33</ci_lower_limit>
            <ci_upper_limit>-18.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-30.87</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>60.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-42.82</ci_lower_limit>
            <ci_upper_limit>-18.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2</title>
        <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (3= hard enough for penetration [but not completely hard]) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2</title>
          <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (3= hard enough for penetration [but not completely hard]) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1 (Week 4) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.36" spread="46.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 (Week 6) N=107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.16" spread="45.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 (Week 6 LOCF) N=112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.28" spread="45.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 (Week 6 Endpoint) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.65" spread="46.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-18.36</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>46.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-27.05</ci_lower_limit>
            <ci_upper_limit>-9.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-22.16</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>45.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-30.84</ci_lower_limit>
            <ci_upper_limit>-13.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-20.28</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>45.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-28.87</ci_lower_limit>
            <ci_upper_limit>-11.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-20.65</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>46.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-29.38</ci_lower_limit>
            <ci_upper_limit>-11.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline</title>
        <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline</title>
          <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 4 (Week 2) N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.27" spread="41.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 (Week 4) N=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.45" spread="44.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 (Week 6) N=98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.10" spread="45.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 (Week 6 LOCF) N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.84" spread="45.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 (Week 6 Endpoint) N=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.13" spread="45.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>33.27</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>41.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>25.17</ci_lower_limit>
            <ci_upper_limit>41.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>61.45</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>44.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>52.61</ci_lower_limit>
            <ci_upper_limit>70.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>66.10</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>45.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>57.05</ci_lower_limit>
            <ci_upper_limit>75.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>64.84</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>45.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>55.91</ci_lower_limit>
            <ci_upper_limit>73.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>65.13</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>45.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>56.14</ci_lower_limit>
            <ci_upper_limit>74.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2</title>
        <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2</title>
          <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 4 (Week 4) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.53" spread="40.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 (Week 6) N=107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.92" spread="41.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 (Week 6 LOCF) N=112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.43" spread="41.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 (Week 6 Endpoint) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.98" spread="42.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>27.53</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>40.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>19.94</ci_lower_limit>
            <ci_upper_limit>35.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>30.92</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>41.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>22.89</ci_lower_limit>
            <ci_upper_limit>38.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>30.43</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>41.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>22.59</ci_lower_limit>
            <ci_upper_limit>38.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>30.98</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>42.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>23.04</ci_lower_limit>
            <ci_upper_limit>38.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline</title>
        <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (hard enough for penetration [but not completely hard]) or 4 (completely hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)</description>
        <time_frame>Week 2, Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline</title>
          <description>Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (hard enough for penetration [but not completely hard]) or 4 (completely hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 or 4 (Week 2) N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.45" spread="46.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 or 4 (Week 4) N=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.30" spread="42.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 or 4 (Week 6) N=98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.31" spread="43.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 or 4 (Week 6 LOCF) N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.57" spread="43.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 or 4 (Week 6 Endpoint) N=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.26" spread="43.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>22.45</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>46.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>13.44</ci_lower_limit>
            <ci_upper_limit>31.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>32.30</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>42.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>23.97</ci_lower_limit>
            <ci_upper_limit>40.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>35.31</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>43.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>26.59</ci_lower_limit>
            <ci_upper_limit>44.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>34.57</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>43.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>26.07</ci_lower_limit>
            <ci_upper_limit>43.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>34.26</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>43.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>25.72</ci_lower_limit>
            <ci_upper_limit>42.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2</title>
        <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (hard enough for penetration [but not completely hard]) or 4 (completely hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)</description>
        <time_frame>Week 4 and Week 6</time_frame>
        <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Sildenafil Citrate</title>
            <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2</title>
          <description>Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (hard enough for penetration [but not completely hard]) or 4 (completely hard) erection hardness based on occasions: 100*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)</description>
          <population>MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.</population>
          <units>per-patient percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 or 4 (Week 4) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.18" spread="29.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 or 4 (Week 6) N=107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.75" spread="29.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 or 4 (Week 6 LOCF ) N=112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.15" spread="31.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 or 4 (Week 6 Endpoint ) N=110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.33" spread="31.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 4 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>9.18</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.61</ci_lower_limit>
            <ci_upper_limit>14.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>8.75</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.15</ci_lower_limit>
            <ci_upper_limit>14.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 LOCF minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.15</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>31.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.32</ci_lower_limit>
            <ci_upper_limit>15.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 6 Endpoint minus Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons. Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>single sample t-test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.33</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>31.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.41</ci_lower_limit>
            <ci_upper_limit>16.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Open Label Sildenafil Citrate</title>
          <description>Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.70</frequency_threshold>
        <default_vocab>MedDRA v11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt;60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt;12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

